161 related articles for article (PubMed ID: 38456403)
1. KRAS Mutation Detection with (2
Liu S; Liu F; Hou X; Zhang Q; Ren Y; Zhu H; Yang Z; Xu X
Mol Pharm; 2024 Apr; 21(4):2034-2042. PubMed ID: 38456403
[TBL] [Abstract][Full Text] [Related]
2. Loss of heterozygosity for Kras
Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
[TBL] [Abstract][Full Text] [Related]
3. PET/MR Imaging of a Lung Metastasis Model of Clear Cell Renal Cell Carcinoma with (2S,4R)-4-[
Pollard AC; Paolillo V; Radaram B; Qureshy S; Li L; Maity T; Wang L; Uddin MN; Wood CG; Karam JA; Pagel MD; Piwnica-Worms D; Millward SW; Fowlkes NW; Norton W; Engel BJ; Pisaneschi F; Zacharias NM
Mol Imaging Biol; 2022 Dec; 24(6):959-972. PubMed ID: 35732988
[TBL] [Abstract][Full Text] [Related]
4. Comparative enzymology of (2S,4R)4-fluoroglutamine and (2S,4R)4-fluoroglutamate.
Cooper AJ; Krasnikov BF; Pinto JT; Kung HF; Li J; Ploessl K
Comp Biochem Physiol B Biochem Mol Biol; 2012 Sep; 163(1):108-20. PubMed ID: 22613816
[TBL] [Abstract][Full Text] [Related]
5. In Vivo PET Assay of Tumor Glutamine Flux and Metabolism: In-Human Trial of
Dunphy MPS; Harding JJ; Venneti S; Zhang H; Burnazi EM; Bromberg J; Omuro AM; Hsieh JJ; Mellinghoff IK; Staton K; Pressl C; Beattie BJ; Zanzonico PB; Gerecitano JF; Kelsen DP; Weber W; Lyashchenko SK; Kung HF; Lewis JS
Radiology; 2018 May; 287(2):667-675. PubMed ID: 29388903
[TBL] [Abstract][Full Text] [Related]
6. First-in-Humans PET Imaging of
Li X; Ye J; Wang J; Quan Z; Li G; Ma W; Zhang M; Yang W; Wang J; Ma T; Kang F; Wang J
J Nucl Med; 2023 Dec; 64(12):1880-1888. PubMed ID: 37827842
[TBL] [Abstract][Full Text] [Related]
7. Exploiting Glutamine Consumption in Atherosclerotic Lesions by Positron Emission Tomography Tracer (2
Palani S; Miner MWG; Virta J; Liljenbäck H; Eskola O; Örd T; Ravindran A; Kaikkonen MU; Knuuti J; Li XG; Saraste A; Roivainen A
Front Immunol; 2022; 13():821423. PubMed ID: 35145523
[TBL] [Abstract][Full Text] [Related]
8. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
9. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract][Full Text] [Related]
10. Fluorination at the 4 position alters the substrate behavior of L-glutamine and L-glutamate: Implications for positron emission tomography of neoplasias.
Jeitner TM; Kristoferson E; Azcona JA; Pinto JT; Stalnecker C; Erickson JW; Kung HF; Li J; Ploessl K; Cooper AJL
J Fluor Chem; 2016 Dec; 192(A):58-67. PubMed ID: 28546645
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of (2S,4S)-4-[
Huang Y; Liu Y; Li C; Li Z; Chen H; Zhang L; Liang Y; Wu Z
Mol Pharm; 2023 Oct; 20(10):5195-5205. PubMed ID: 37647563
[TBL] [Abstract][Full Text] [Related]
12. Loss of Heterozygosity for
Ma Y; Ling S; Li Y; Hu M; Kong B; Huang P; Liu H
Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743139
[TBL] [Abstract][Full Text] [Related]
13. PET Imaging of
Liu F; Xu X; Zhu H; Zhang Y; Yang J; Zhang L; Li N; Zhu L; Kung HF; Yang Z
Mol Pharm; 2018 Aug; 15(8):3448-3455. PubMed ID: 29985631
[TBL] [Abstract][Full Text] [Related]
14. Metabolic Evaluation of MYCN-Amplified Neuroblastoma by 4-[
Li C; Huang S; Guo J; Wang C; Huang Z; Huang R; Liu L; Liang S; Wang H
Mol Imaging Biol; 2019 Dec; 21(6):1117-1126. PubMed ID: 30850970
[TBL] [Abstract][Full Text] [Related]
15. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
16.
Shen H; Lundy J; Strickland AH; Harris M; Swan M; Desmond C; Jenkins BJ; Croagh D
Cells; 2022 Oct; 11(19):. PubMed ID: 36231137
[No Abstract] [Full Text] [Related]
17. CXCR2 signaling regulates KRAS(G¹²D)-induced autocrine growth of pancreatic cancer.
Purohit A; Varney M; Rachagani S; Ouellette MM; Batra SK; Singh RK
Oncotarget; 2016 Feb; 7(6):7280-96. PubMed ID: 26771140
[TBL] [Abstract][Full Text] [Related]
18. Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer.
Lee MR; Woo SM; Kim MK; Han SS; Park SJ; Lee WJ; Lee DE; Choi SI; Choi W; Yoon KA; Chun JW; Kim YH; Kong SY
Cancer Sci; 2024 Apr; 115(4):1283-1295. PubMed ID: 38348576
[TBL] [Abstract][Full Text] [Related]
19. Krüppel-like Factor 5, Increased in Pancreatic Ductal Adenocarcinoma, Promotes Proliferation, Acinar-to-Ductal Metaplasia, Pancreatic Intraepithelial Neoplasia, and Tumor Growth in Mice.
He P; Yang JW; Yang VW; Bialkowska AB
Gastroenterology; 2018 Apr; 154(5):1494-1508.e13. PubMed ID: 29248441
[TBL] [Abstract][Full Text] [Related]
20. Loss of Pten and Activation of Kras Synergistically Induce Formation of Intraductal Papillary Mucinous Neoplasia From Pancreatic Ductal Cells in Mice.
Kopp JL; Dubois CL; Schaeffer DF; Samani A; Taghizadeh F; Cowan RW; Rhim AD; Stiles BL; Valasek M; Sander M
Gastroenterology; 2018 Apr; 154(5):1509-1523.e5. PubMed ID: 29273451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
